Jay R. Venkatesan - 15 Jul 2022 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 15 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jul 2022, 16:38:14 UTC
Prior SEC filing: 27 May 2022
Next SEC filing: 29 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ James Paul Rickey, attorney-in-fact

Key filing fact

Jay R. Venkatesan filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 19 Jul 2022.

Key facts

This page summarizes Jay R. Venkatesan's Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Jul 2022, 16:38.

Change

Previous filing in this sequence was filed on 27 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALPN transaction

Common Stock

Options Exercise

Transaction value: $9,028
Shares: +20,063
Change %: +9.2%
Price: $0.4500^*
Shares after: 238,126
Date: 15 Jul 2022
Ownership: Direct

ALPN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 18,633
Date: 15 Jul 2022
Ownership: By Raj Venkatesan as UTMA custodian for Reid Coleman Venkatesan
Footnotes: F1, F2

ALPN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,600,980
Date: 15 Jul 2022
Ownership: By Alpine ImmunoSciences, L.P.
Footnotes: F1, F3

ALPN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 18,633
Date: 15 Jul 2022
Ownership: By Raj Venkatesan as UTMA custodian for Nathaniel Graham Venkatesan
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALPN transaction Derivative

Stock Option (Right to buy)

Options Exercise

Transaction value: $9,028
Shares: -20,063
Change %: -22%
Price: $0.4500^*
Shares after: 70,000
Date: 15 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,063
Exercise price: $0.4500
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F2

These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under the California Uniform Transfers to Minors Act.

Footnote F3

Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.

Footnote F4

Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio.

Footnote F5

The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions.